Ali Tehrani, Zymeworks CEO

Zymeworks squares up with Her­ceptin af­ter HER2 bis­pe­cif­ic aces mid-stage test in esophageal can­cer

Roche’s Her­ceptin has long stood as stan­dard of care across mul­ti­ple ad­vanced can­cers, but a suite of next-gen play­ers are look­ing to beat the ag­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.